Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | The potential of targeting dihydroorotate dehydrogenase in CML

Giuseppe Saglio • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Giuseppe Saglio, MD, University of Turin, Turin, Italy, comments on the potential of targeting dihydroorotate dehydrogenase (DHODH) in chronic myeloid leukemia (CML), explaining that combining DHODH inhibition with other existing therapeutic strategies might improve the number of patients eligible for tyrosine kinase inhibitor (TKI) discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals